Cavitary Lung Disease in COVID-19
Syeda Fatima Hassan MD1, Nathaniel Rosal DO1, Rameesha Mehreen MD1, Richard Friedenheim MD2
1. Department of Internal Medicine, Abington Jefferson Health, Abington, PA
2. Department of Pulmonary and Critical Care, Abington Jefferson Health, Abington, PA

Introduction
Cavitary lung disease has been described in many different pathologies, namely fungal, mycobacterial, and autoimmune diseases. After roughly one year since the onset of the COVID-19 pandemic, literature on cavitary lung disease in patients with the SARS-CoV2 virus is emerging.

Case
A 63-year-old male with no significant past medical history presented with a chief complaint of shortness of breath in the setting of a known COVID-19 infection. After nine days of self-quarantining, the patient presented to the hospital with minimal improvement in symptoms. The patient was intubated for refractory hypoxia, though ultimately required extracorporeal membrane oxygenation (ECMO). After one month on ECMO, the patient was found to have a cavitary lesion of the left middle lobe. Throughout his hospitalization, he was treated with Remdesivir, dexamethasone for COVID-19, as well as broad spectrum antimicrobials vancomycin, piperacillin/tazobactam, and anidulofungin. Blood, sputum, and bronchoalveolar lavage cultures were obtained for bacterial, fungal, acid fast, and cryptococcus, all of which revealed no etiology. Aspergillus Galactomannan antigen, HIV-1 p24 antigen and HIV-1/HIV-2 antibody, cryptococcus antigen, were not detected in the blood. SARS-CoV 2 Nucleic acid amplification test however, was persistently positive. His antimicrobial regimen was discontinued after sufficient empiric coverage. Subsequent CT scans of the chest were significant for multiple new cavitary lesions. Despite these findings, the patient was successfully decannulated from ECMO, though ultimately required tracheostomy for weaning of mechanical ventilation and percutaneous endoscopic gastrostomy tube for nutrition before discharge to a skilled nursing and rehabilitation facility.

Further studies and case reports may shed light on the long term effects of this finding in COVID-19 patients.

Discussion
Cavitary lung lesions may represent a late finding in COVID-19 pneumonitis though the mechanism of their development is still being investigated. Hypothesized mechanisms include specific inflammatory pathways, Micro infarctions, and/or intra-alveolar hemorrhage and necrosis of parenchymal cells.

Conclusion
COVID 19 pneumonitis should be a consideration in the differential diagnosis in patient with cavitary lesions in the lungs.

References